Capmatinib is a member of the class of imidazotriazines that is imidazo[1,2-b][1,2,4]triazine substituted by 3-fluoro-4-(methylcarbamoyl)phenyl and quinolin-6-ylmethyl groups at positions 2 and 7, respectively. It is a c-Met receptor tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer with MET exon 14 skipping mutation. It has a role as an antineoplastic agent, a hepatotoxic agent, an apoptosis inducer and a c-Met tyrosine kinase inhibitor. It is a secondary carboxamide, a member of benzamides, a member of quinolines, an imidazotriazine and a member of monofluorobenzenes.
